{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:55:12Z","timestamp":1786985712252,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,12]],"date-time":"2027-05-12T00:00:00Z","timestamp":1810080000000},"content-version":"am","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000049","name":"NIA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cardfail.2026.01.014","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:52:56Z","timestamp":1778572376000},"page":"811-820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multidimensional Assessment of Disease Progression in a Contemporary Population With Transthyretin Amyloid Cardiomyopathy: Integrating Clinical Parameters, Biomarkers, Functionality, and Patient-Reported Outcomes"],"prefix":"10.1016","volume":"32","author":[{"given":"DIMITRIOS","family":"BAMPATSIAS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JULIANA","family":"LEVY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALFONSINA","family":"MIRABAL-SANTOS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARGARET","family":"CUOMO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YEVGENIY","family":"BRAILOVSKY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KARAN","family":"WATS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SERGIO","family":"TERUYA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-5008","authenticated-orcid":false,"given":"MATHEW S.","family":"MAURER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2026.01.014_bib0001","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/ehf2.13541","article-title":"Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT","volume":"8","author":"Nativi-Nicolau","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0002","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0003","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0004","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0005","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0006","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0007","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.3198","article-title":"Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety","volume":"26","author":"Lang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0008","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/eurheartj\/ehae140","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"45","author":"Ioannou","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0009","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0010","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/13506129.2024.2376202","article-title":"Response to therapy with tafamidis 61\u2009mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval","volume":"31","author":"Aus dem Siepen","year":"2024","journal-title":"Amyloid"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0011","doi-asserted-by":"crossref","unstructured":"Ioannou A, Cappelli F, Emdin M, Nitsche C, Longhi S, Masri A, et al. Stratifying disease progression in patients with cardiac ATTR amyloidosis. J Am Coll Cardiol 2024 (Published online March 1, 2024. doi: 10.1016\/j.jacc.2023.12.036","DOI":"10.1016\/j.jacc.2023.12.036"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0012","doi-asserted-by":"crossref","unstructured":"Ioannou A, Razvi,Y, Porcari A, Rauf MU, Martinez-Naharro A, Venneri, et al. Kidney outcomes in transthyretin amyloid cardiomyopathy. JAMA Cardiol (Published online November 17, 2024). doi: 10.1001\/jamacardio.2024.4578","DOI":"10.1001\/jamacardio.2024.4578"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0013","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jacc.2024.04.011","article-title":"Prognostic value of a 6-Minute Walk Test in patients with transthyretin cardiac amyloidosis","volume":"84","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102553","article-title":"Using patient-reported outcomes to assess transthyretin amyloid cardiomyopathy progression in patients treated with disease-modifying therapy","volume":"13","author":"Levy","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0015","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0016","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC Cardio Oncol"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0017","doi-asserted-by":"crossref","unstructured":"Zeldin L, Eichler JBS, Teruya SL, Weinsaft AY, Mirabal A, Cuomo MO, et al. Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy. Eur J Heart Fail (Published online December 5, 2024). doi: 10.1002\/ejhf.3540","DOI":"10.1016\/S0735-1097(24)02519-1"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0018","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jgs.17218","article-title":"Prefrailty, impairment in physical function, and risk of incident heart failure among older adults","volume":"69","author":"Segar","year":"2021","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0019","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC State-of-the-Art Review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0020","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0021","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.3390\/jcm13133730","article-title":"Impact of tafamidis on delaying clinical, functional, and structural cardiac changes in patients with wild-type transthyretin amyloid cardiomyopathy","volume":"13","author":"Palmiero","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0022","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy","volume":"23","author":"Rettl","year":"2022","journal-title":"Eur Heart J Cardiovasc Imag"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0023","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/ejhf.2606","article-title":"Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis","volume":"24","author":"Chacko","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0024","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.cardfail.2024.02.014","article-title":"Temporal outcomes of patients diagnosed with transthyretin cardiac amyloidosis","volume":"30","author":"Chan","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"ATTRibute-CM Investigators. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.01.014_bib0026","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"HELIOS-B Trial Investigators. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426000801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426000801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:54:16Z","timestamp":1783112056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916426000801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1071916426000801"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.01.014","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multidimensional Assessment of Disease Progression in a Contemporary Population With Transthyretin Amyloid Cardiomyopathy: Integrating Clinical Parameters, Biomarkers, Functionality, and Patient-Reported Outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.02.021","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}